Silvercrest Asset Management Group LLC Acquires 1,438 Shares of Insulet Co. (NASDAQ:PODD)

Silvercrest Asset Management Group LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 18.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,364 shares of the medical instruments supplier's stock after purchasing an additional 1,438 shares during the quarter. Silvercrest Asset Management Group LLC's holdings in Insulet were worth $2,445,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Horizon Investments LLC raised its stake in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 42 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after acquiring an additional 43 shares during the period. Wilmington Savings Fund Society FSB raised its stake in shares of Insulet by 9.6% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock valued at $140,000 after acquiring an additional 47 shares during the period. Envestnet Portfolio Solutions Inc. raised its stake in shares of Insulet by 2.3% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after acquiring an additional 48 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Insulet by 5.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock valued at $274,000 after acquiring an additional 50 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their target price on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Citigroup increased their target price on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Canaccord Genuity Group raised their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research note on Monday, April 28th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $306.53.

Insulet Stock Up 0.3%

Shares of Insulet stock opened at $325.84 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 1 year low of $170.67 and a 1 year high of $326.50. The firm's 50-day moving average is $265.69 and its two-hundred day moving average is $267.57. The stock has a market cap of $22.93 billion, a price-to-earnings ratio of 56.28, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same period in the prior year, the business earned $0.73 EPS. The firm's quarterly revenue was up 28.8% on a year-over-year basis. As a group, research analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.